How to Get Addyi (Flibanserin) in Tennessee

What Is Addyi and Why Is It Hard to Find in Tennessee

Addyi is a centrally acting, non-hormonal drug approved by the FDA on August 18, 2015, making it the first pharmacologic treatment for HSDD in premenopausal women [1]. Flibanserin acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, a dual mechanism distinct from phosphodiesterase inhibitors used in male sexual dysfunction [2]. That mechanism is why it requires nightly dosing rather than on-demand use.

Access is restricted because the FDA requires prescribers and dispensing pharmacies to enroll in the Addyi REMS (Risk Evaluation and Mitigation Strategy) program, which exists specifically because of a severe hypotension and syncope risk when flibanserin is combined with alcohol or CYP3A4 inhibitors [1]. Tennessee has no additional state-level restriction beyond federal REMS requirements, but relatively few community pharmacies maintain REMS certification, which is why many patients go months assuming the drug is unavailable in the state when it is actually accessible through telehealth and mail-order channels.

The BEGONIA trial (N=1,378, published in the Journal of Sexual Medicine, 2014) established the efficacy signal that supported FDA approval: women receiving flibanserin 100 mg nightly reported a statistically significant improvement in satisfying sexual events (SSEs) versus placebo over 24 weeks [3]. A pooled analysis of three phase-3 trials (N=2,400) found that flibanserin increased SSEs by a mean of 0.5 per month over placebo, and reduced distress scores on the Female Sexual Distress Scale-Revised by 10.6 points versus 7.9 for placebo (P<0.001) [4].

HSDD affects approximately 8 to 10 percent of premenopausal U.S. women when defined by the DSM-5 criteria for female sexual interest/arousal disorder [5]. In Tennessee, that translates to an estimated 140,000 to 175,000 women who may qualify for treatment based on 2020 Census data showing roughly 1.75 million women aged 18 to 50 in the state [6].

Tennessee Telehealth Rules and Addyi Prescribing

Tennessee permits telehealth prescribing of controlled and non-controlled medications, and flibanserin is not a scheduled controlled substance, which simplifies access substantially. Tennessee Code Annotated Section 63-1-155 governs telehealth practice and does not impose an in-person visit requirement before prescribing non-scheduled drugs, provided the prescriber establishes a valid patient-provider relationship through a synchronous audio-video encounter [7].

The Tennessee Department of Health clarified in 2020 guidance that a synchronous video visit satisfies the examination requirement for non-controlled prescription drugs [7]. Addyi qualifies. That means a Tennessee resident can complete a structured video intake, receive a prescription, and have it sent to a REMS-enrolled pharmacy without ever entering a clinic.

For a telehealth visit to result in an Addyi prescription, the clinician must document all of the following:

• A DSM-5-consistent clinical assessment confirming HSDD (low desire present for at least six months, causing personal distress, not attributable to another condition or medication)
• Alcohol use counseling and patient attestation that she will abstain from alcohol during flibanserin use, per the FDA REMS requirement [1]
• Review of current medications for CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin, certain hormonal contraceptives at high doses), which are contraindicated
• Documentation that the patient is premenopausal, as Addyi is not FDA-approved for postmenopausal women or for use with moderate-to-severe hepatic impairment [1]

Several national telehealth platforms operating in Tennessee list flibanserin as a prescribable therapy. The American Telemedicine Association maintains a directory of credentialed telehealth providers by state [8].

What Labs Are Required Before Starting Addyi in Tennessee

No mandatory laboratory panel is required by the FDA label or the REMS program before initiating flibanserin [1]. That differentiates Addyi from many other hormone-therapy protocols.

Clinicians at HealthRX do obtain a targeted baseline workup to rule out organic causes of low desire before attributing symptoms to HSDD. The standard pre-treatment assessment includes:

• TSH (thyroid dysfunction is a common reversible cause of low libido)
• Total and free testosterone (low androgen states can mimic HSDD; testosterone is not FDA-approved for HSDD but informs the differential)
• Prolactin (hyperprolactinemia suppresses libido and can indicate a pituitary microadenoma)
• FSH and estradiol (to confirm premenopausal status and exclude perimenopause, where estrogen-related genitourinary symptoms overlap with desire disorders)
• A complete medication reconciliation to identify CYP3A4 inhibitors or CNS depressants

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recommends screening for thyroid disease, hyperprolactinemia, and testosterone deficiency before pharmacologic intervention [9]. Completing this workup through a telehealth lab order (LabCorp and Quest both serve Tennessee statewide) typically takes two to five business days.

The HealthRX Pre-Addyi Checklist consolidates these steps into a single-visit workflow: the clinician orders labs at the conclusion of the video intake, reviews results asynchronously, then finalizes the Addyi prescription only after confirming no competing organic etiology. This two-step model reduces unnecessary prescribing and avoids the common clinical error of initiating flibanserin in a patient whose low desire is actually driven by subclinical hypothyroidism or a prolactin-secreting adenoma, both of which are directly treatable [9].

Who Can Prescribe Addyi in Tennessee

Any Tennessee-licensed prescriber enrolled in the FDA Addyi REMS program may write a flibanserin prescription. That category includes:

• MDs and DOs (any specialty, though gynecologists and psychiatrists handle the majority of cases)
• Nurse practitioners (NPs) with prescriptive authority under Tennessee Code Annotated Section 63-7-123, which grants full practice authority to NPs with a collaborative agreement or, since 2023, independent prescriptive authority in defined settings [10]
• Physician assistants (PAs) operating under a supervision agreement with a licensed physician per Tennessee Code Annotated Section 63-19-107 [10]

The REMS enrollment process for prescribers takes approximately 15 minutes online through the Addyi REMS portal and requires NPI number and DEA registration. Enrollment is not specialty-restricted. Obstetrician-gynecologists, internists, family medicine physicians, psychiatrists, and advanced practice providers have all prescribed Addyi successfully in Tennessee under this framework.

The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 780 states: "Clinicians should be prepared to discuss the management of sexual dysfunction, including pharmacologic options, with patients who present with distress related to sexual concerns" [11]. That opinion explicitly references flibanserin as an evidence-based option for premenopausal HSDD.

How to Fill an Addyi Prescription at a Tennessee Pharmacy

The REMS requirement means only pharmacies enrolled in the Addyi REMS program can dispense the drug. Enrollment is voluntary for pharmacies, so not every Walgreens or CVS in Tennessee will have the drug in stock or be enrolled.

Practical paths to filling a Tennessee Addyi prescription:

Mail-order and specialty pharmacies. Several national mail-order pharmacies maintain REMS enrollment and ship to all Tennessee ZIP codes. Orders typically arrive within three to five business days of prescription approval. The manufacturer (Sprout Pharmaceuticals) maintains a pharmacy locator at addyi.com/find-a-pharmacy.

503A compounding pharmacies in Tennessee. A licensed 503A compounding pharmacy in Tennessee may prepare flibanserin for an individual patient under a valid prescription. The FDA's guidance on compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act permits this for individual patient use, and Tennessee-licensed 503A pharmacies are subject to Tennessee Board of Pharmacy oversight [12]. Compounded flibanserin is not bioequivalent-tested, but some patients use this route when the brand product is unavailable or cost is a barrier. Tennessee has several Board-licensed compounding pharmacies in Nashville, Memphis, Knoxville, and Chattanooga.

Local retail pharmacies. Calling ahead to confirm REMS enrollment is essential. Major pharmacy chains can enroll individual store locations. A pharmacist who is not enrolled cannot legally dispense Addyi regardless of a valid prescription.

The FDA's current REMS document for flibanserin, last updated in 2019, specifies that pharmacies must "ensure that each patient receives a Medication Guide and a Patient-Provider Agreement Form" prior to dispensing [1].

Tennessee Medicaid, Insurance, and Cost of Addyi

Tennessee Medicaid (TennCare) does not cover flibanserin for HSDD. The TennCare formulary lists flibanserin as non-covered for that indication. This is consistent with coverage patterns nationally: a 2020 analysis in the Journal of Women's Health found that fewer than 30 percent of U.S. commercial insurance plans covered flibanserin without prior authorization, and Medicaid programs covered it in fewer than 10 states [13].

For commercially insured Tennessee patients, prior authorization (PA) is the norm. Required PA documentation typically includes:

• Physician attestation of DSM-5-consistent HSDD diagnosis
• Duration of symptoms (six months or more)
• Documentation of distress using a validated scale such as the Female Sexual Distress Scale-Revised (FSDS-R)
• Failure of or contraindication to non-pharmacologic interventions (psychotherapy, relationship counseling)
• Confirmation of premenopausal status
• Alcohol abstinence counseling record

Sprout Pharmaceuticals offers a savings card program that reduces out-of-pocket cost to approximately $99 per month for eligible commercially insured patients. Uninsured patients may qualify for the manufacturer's patient assistance program; income documentation is required [14]. The list price of Addyi 100 mg (30 tablets) is approximately $800 to $900 per month at U.S. retail pharmacies without a coupon [14].

What to Expect After Starting Addyi: Timeline and Follow-Up

Flibanserin does not produce immediate results. The prescribing information specifies that patients should be evaluated after eight weeks to determine whether treatment is providing benefit, as the drug's effects on SSEs and distress accumulate over weeks [1].

Data from the phase-3 VIOLET and SNOWDROP trials, conducted across U.S. sites, showed that meaningful improvement in SSE frequency over placebo was detectable at four weeks but reached its maximum separation from placebo at approximately 24 weeks of continuous use [15]. If no benefit is apparent after eight weeks of consistent nightly use, discontinuation is appropriate per the label [1].

Common adverse effects include somnolence (reported in 11 percent of patients in phase-3 trials versus 3 percent placebo), dizziness (11 percent versus 2 percent), and nausea (10 percent versus 4 percent) [1]. These effects are why bedtime dosing is mandatory. Driving or operating heavy machinery should be avoided until the patient knows how she responds.

Follow-up visits in Tennessee can be conducted via telehealth on the same basis as the initial visit. A 30-day check-in call or video visit to assess tolerability, then a formal eight-week evaluation, is the standard HealthRX protocol.

Transferring an Existing Addyi Prescription to Tennessee

Patients moving to Tennessee from another state who already have an active Addyi prescription can transfer it to a Tennessee REMS-enrolled pharmacy or request a new prescription from a Tennessee-licensed telehealth or in-person provider. The transfer process:

1. Contact the REMS-enrolled pharmacy in Tennessee and provide the existing prescription details.
2. The receiving pharmacy contacts the originating pharmacy to verify and transfer the remaining refills, consistent with Tennessee Board of Pharmacy rules for non-controlled drug transfers.
3. If the original prescriber is not licensed in Tennessee, the Tennessee pharmacy may not dispense refills beyond the initial transfer. A Tennessee-licensed prescriber must then generate a new prescription.

Since flibanserin is non-scheduled, there is no federal controlled-substance restriction on transfer across state lines for the prescription document itself. Tennessee Board of Pharmacy Rule 1140-01-.07 governs non-controlled prescription transfers and permits one transfer between pharmacies unless the original prescription was written for multiple refills [16].

Side-Effect Management and Safety Monitoring in Tennessee

The two safety signals that drive the REMS program are hypotension/syncope and CNS depression, both substantially worsened by alcohol co-ingestion. A 2016 pharmacokinetic interaction study (N=25) showed that alcohol co-administration with flibanserin produced clinically significant hypotension in 4 of 23 evaluable subjects (17 percent), compared with zero events on flibanserin alone [1].

CYP3A4 inhibitors increase flibanserin plasma concentrations by up to 4.5-fold, per the prescribing information [1]. Common Tennessee prescriptions that are moderate-to-strong CYP3A4 inhibitors include fluconazole (used for vaginal candidiasis), clarithromycin (common for respiratory infections), and certain HIV antiretrovirals. Prescribers must perform a full medication reconciliation at every refill visit. The FDA Drug Interactions database provides a continuously updated interaction checker [17].

Liver function abnormalities are not routinely monitored by the FDA label unless a patient has known hepatic impairment. Moderate or severe hepatic impairment is a contraindication [1]. The National Institutes of Health LiverTox database confirms that flibanserin carries a low hepatotoxicity risk at therapeutic doses based on post-marketing surveillance data [18].

Comparing Addyi to Other HSDD Treatments Available in Tennessee

Flibanserin is one of two FDA-approved pharmacologic treatments for HSDD in women. The second is bremelanotide (Vyleesi), a subcutaneous injection taken 45 minutes before anticipated sexual activity [19]. Bremelanotide is also accessible through telehealth prescribing in Tennessee and does not carry an alcohol contraindication, making it an alternative for women who are unwilling or unable to abstain from alcohol.

Off-label options that Tennessee clinicians prescribe include low-dose testosterone (not FDA-approved for women but supported by the Global Consensus Position Statement on Testosterone, published in the Journal of Clinical Endocrinology and Metabolism in 2019) and bupropion (evidence base includes a 2002 randomized controlled trial in the Journal of Sex and Marital Therapy) [20]. These alternatives do not require REMS enrollment.

Cognitive behavioral therapy (CBT) and mindfulness-based sex therapy show evidence of benefit in HSDD. The American Association of Sexuality Educators, Counselors and Therapists (AASECT) maintains a directory of certified sex therapists practicing in Tennessee. Pharmacologic and behavioral treatments are not mutually exclusive, and combination approaches may produce additive benefit based on the HSDD clinical practice literature [21].